KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Cash from Operations (2016 - 2025)

TherapeuticsMD's Cash from Operations history spans 16 years, with the latest figure at 375000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 2105.88% year-over-year to 375000.0; the TTM value through Dec 2025 reached 2454000.0, up 109.74%, while the annual FY2025 figure was 2454000.0, 109.74% up from the prior year.
  • Cash from Operations reached 375000.0 in Q4 2025 per TXMD's latest filing, down from 999000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 48002000.0 in Q4 2021 to a low of 38380000.0 in Q1 2021.
  • Average Cash from Operations over 5 years is 3261550.0, with a median of 150000.0 recorded in 2024.
  • Peak YoY movement for Cash from Operations: crashed 134.03% in 2023, then soared 2105.88% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 48002000.0 in 2021, then tumbled by 37.01% to 30236000.0 in 2022, then tumbled by 116.4% to 4960000.0 in 2023, then soared by 100.34% to 17000.0 in 2024, then skyrocketed by 2105.88% to 375000.0 in 2025.
  • Per Business Quant, the three most recent readings for TXMD's Cash from Operations are 375000.0 (Q4 2025), 999000.0 (Q3 2025), and 381000.0 (Q2 2025).